Company: LCTX
Filing Date: 2025-03-10
Form Type: 10-K
Source: 0000950170-25-036309
Chunk: 249

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-03-10
Form: 10-K
Item: Item 8
Chunk 249
---
582
    )

    BALANCE - December 31, 2024

    220,416

    $
    484,722

    $
    (403,465
    )
     
    $
    (1,369
    )
     
    $
    (2,876
    )
     
    $
    77,012

See accompanying notes to the consolidated financial statements.

100

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

    Year Ended December 31,

    2024

    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:

    Net loss attributable to Lineage
     
    $
    (18,609
    )
     
    $
    (21,486
    )

    Net loss attributable to noncontrolling interest

    27

    7

    Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc.    to net cash used in operating activities:

    Issuance costs for common stock warrant liabilities

    688

    —

    Loss on marketable equity securities, net

    8

    176

    Accretion of income on marketable debt securities

    (229
    )

    (679
    )

    Depreciation and amortization expense

    587

    562

    Change in right-of-use assets and liabilities

    (42
    )

    91

    Amortization of intangible assets

    22

    130

    Stock-based compensation

    5,077

    4,640

    Change in fair value of warrant liability

    (2,128
    )

    —

    Deferred income tax benefit

    —

    (1,803
    )

    Foreign currency remeasurement and other loss

    273

    600

    Changes in operating assets and liabilities:

    Accounts receivable

    106

    (446
    )

    Prepaid expenses and other current assets

    489

    (418
    )

    Accounts payable and accrued liabilities

    (1,681
    )

    (2,295
    )

    Deferred revenue

    (7,680
    )

    (7,645
    )

    Net cash used in operating activities

    (23,092